Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Closure Medical (CLSR) fomerly Tri-Point Medical (TPMC) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (126)	3/21/1998 6:19:00 PM
From: RevMikeB	Read Replies (1) \| Respond to of 184

>>Closure has a 1st generation "glue". There are other companies that are behind closure in the approval process, but who believe they have a better product. If those other firms are correct, then closure's future big earnings that is projected would not occur, since 3 or 4 years from now, they will have several competitors, and we should think competitors with better products.<< Yea, but 3 or 4 years from now is a long time for any drug. To have a corner on the market that long is huge! (I think!?) All drugs that are making money now, have others right behind them that are better. That's the nature of the business. But, can CLSR compete? That's the question. And how far will prices of glues fall? In an AP article it says: Emergency room physicians may soon glue cuts back together, painlessly, rather than using stitches or staples. And that would be just a start. Doctors already are using surgical glues in experimental heart, lung and eye surgery, mastectomies and knee replacements.''It's a cutting-edge area, with many competitive technologies going after a huge market that could revolutionize surgery in the next millennium,'' said Gwen Como of San Diego-based Protein Polymer Technologies Inc., one of the companies working on commercial development. Couldn't Closure grow in these other areas too with new glues? They do spend money on R&D, I hope? >>>My understanding is that the company has problems with infection rates being too high. I suspect that over the next few months, more information about competitive products will surface<<< Sounds like you don't like this stock. I heard that when Dermabond was recommended for approval, infection was minimal.